<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04604730</url>
  </required_header>
  <id_info>
    <org_study_id>2019/409/HP</org_study_id>
    <nct_id>NCT04604730</nct_id>
  </id_info>
  <brief_title>Role of Protective Stoma After Primary Anastomosis for Generalized Peritonitis Due to Perforated Diverticulitis</brief_title>
  <acronym>DIVERTI 2</acronym>
  <official_title>Role of Protective Stoma After Primary Anastomosis for Generalized Peritonitis Due to Perforated Diverticulitis: a Prospective Multicenter Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Rouen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Rouen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to be a multicentre, prospective, comparative, randomised trial,&#xD;
      evaluating the efficacy of two surgical strategies for the treatment of generalised&#xD;
      peritonitis due to perforated diverticulitis. Results will be analysed according to an&#xD;
      intention to treat principle (after selection and patient consent). Immediately before&#xD;
      surgery, the patient will be randomly assigned to sigmoidectomy with primary anastomosis or&#xD;
      to sigmoidectomy with primary anastomosis and diverting stoma. Sigmoidectomy will be&#xD;
      performed through a midline laparotomy or laparoscopically according to the standard&#xD;
      technique. In the control arm, a protective stoma will be performed at the end of surgery. A&#xD;
      stoma reversal operation will be performed at least 3 months after the first operation and&#xD;
      after performing a cologram by water soluble contrast between 4 and 8 weeks to check for the&#xD;
      absence of fistula or stenosis at the level of the anastomosis. Stoma reversal will be&#xD;
      performed with a trephine incision.&#xD;
&#xD;
      Post-stoma closure follow-ups will be planned and all morbidity/mortality will be recorded.&#xD;
      All patients will be examined at 6, 12, and 24 weeks after the initial surgery, in the&#xD;
      surgical department where they were operated; a final study visit will be carried out 12&#xD;
      months (evaluation of primary endpoint) after surgery. The parameters explored at medical&#xD;
      examinations will be: • Occurrence of complications • Quality of life assessment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to be a multicentre, prospective, comparative, randomised trial,&#xD;
      evaluating the efficacy of two surgical strategies for the treatment of generalised&#xD;
      peritonitis due to perforated diverticulitis. Results will be analysed according to an&#xD;
      intention to treat principle. The diagnosis will be established by the surgeon investigator&#xD;
      on clinical data, imagery and operative findings during a laparotomy or laparoscopy. After&#xD;
      selection and patient consent and immediately before surgery, the patient will be randomly&#xD;
      assigned to sigmoidectomy with primary anastomosis or to sigmoidectomy with primary&#xD;
      anastomosis and diverting stoma. Sigmoidectomy will be performed through a midline laparotomy&#xD;
      or laparoscopically according to the standard technique, with lateral to medial mobilisation&#xD;
      of the left colon, mobilisation of splenic flexure and identification of left ureter. The&#xD;
      rectosigmoid junction will be exposed and transected with a stapler. Proximal section will be&#xD;
      performed on a healthy colonic segment. The anastomosis will be performed according to the&#xD;
      surgeon investigator's preference (mechanical or manual anastomosis; end to end or side to&#xD;
      end).&#xD;
&#xD;
      Decisions to clean the colon intraoperatively and to place a drain will be left to the&#xD;
      surgeon's discretion. In the control arm, a protective stoma will be performed at the end of&#xD;
      surgery. A stoma reversal operation will be performed at least 3 months after the first&#xD;
      operation and after performing a cologram by water soluble contrast between 4 and 8 weeks to&#xD;
      check for the absence of fistula or stenosis at the level of the anastomosis. Stoma reversal&#xD;
      will be performed with a trephine incision.&#xD;
&#xD;
      Post-stoma closure follow-ups will be planned and all morbidity/mortality will be recorded.&#xD;
      All patients will be examined at 6, 12, and 24 weeks after the initial surgery, in the&#xD;
      surgical department where they were operated; a final study visit will be carried out 12&#xD;
      months (evaluation of primary endpoint) after surgery. The parameters explored at medical&#xD;
      examinations will be: • Occurrence of complications • Quality of life assessment&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 11, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sequential assignment</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of overall morbidity between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months posteoperatively</time_frame>
    <description>Overall morbidity graded 0 to 5 according to the Clavien-Dindo classification All complications occurring during hospitalization will be collected. Late complications occurring after hospitalization will be collected during follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of the rate of death between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>3 months postoperatively</time_frame>
    <description>rate of death at 3 months after surgery (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the rate of reinterventions between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>the rate of reinterventions after the surgery (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the rate of incisional surgical site infection (SSI) between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>the rate of incisional SSI (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the rate of organ/space SSI between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>the rate of organ/space SSI (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the rate of wound disruptions between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>the rate of wound disruptions (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the rate of anastomotic leaks between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months postoperatively</time_frame>
    <description>the rate of anastomotic leaks (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of operating time between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>surgery</time_frame>
    <description>time of surgery (hours)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of length of postoperative hospital stay between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>Length of postoperative hospital stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of Intensive Care Unit (ICU) length of stay between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>6 months postoperatively</time_frame>
    <description>ICU length of stay (days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the number of patients alive without stoma between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months after initial surgery</time_frame>
    <description>Number of patients alive without stoma at 12 months after initial surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the quality of life between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>6, 12, 26 and 52 weeks after primary surgery</time_frame>
    <description>Quality of life evaluated using the Short Form Health Survey (SF-36) questionnaire at baseline, 6, 12, 26 and 52 weeks after primary surgery Score from 1 to 30</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the quality of life between &quot;with protective stoma&quot; and &quot;without protective stoma&quot; with &quot;EuroQol-5 Dimensions&quot; questionnaire</measure>
    <time_frame>6, 12, 26 and 52 weeks after primary surgery</time_frame>
    <description>Quality of life evaluated using EuroQol-5 Dimensions (EQ-5D) questionnaire at baseline, 6, 12, 26 and 52 weeks after primary surgery Each dimension has three levels of response: no problems (coded 1), some problems (coded 2) and major problems (coded 3), which defines 243 possible health states (35), to which can be added unconscious and dead states, for a total of 245 states. Thus, the health states range from &quot;11111&quot; (no problems on all dimensions) to &quot;33333&quot;: major problems on all dimensions + visual analog scale from 0 to 100, 0 being the worst and 100 the best</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the quality of life between &quot;with protective stoma&quot; and &quot;without protective stoma&quot; with the Gastrintestinal Quality of Life Index questionnaire</measure>
    <time_frame>6, 12, 26 and 52 weeks after primary surgery</time_frame>
    <description>Quality of life evaluated using Ethe Gastrintestinal Quality of Life Index questionnaire at baseline, 6, 12, 26 and 52 weeks after primary surgery Score from 0 to 144, the higher the score, the better the quality of life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of the cost utility between &quot;with protective stoma&quot; and &quot;without protective stoma&quot;</measure>
    <time_frame>12 months after primary surgery</time_frame>
    <description>Quality-Adjusted Life Year (QALY) derived from the EQ5D-5L questionnaire</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">204</enrollment>
  <condition>Peritonitis</condition>
  <arm_group>
    <arm_group_label>Primary anastomosis without protective stoma</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Primary anastomosis without protective stoma</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Anastomosis with protective stoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Anastomosis with protective stoma</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Primary anastomosis without protective stoma</intervention_name>
    <description>Primary anastomosis without protective stoma</description>
    <arm_group_label>Primary anastomosis without protective stoma</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Anastomosis with protective stoma</intervention_name>
    <description>Anastomosis with protective stoma</description>
    <arm_group_label>Anastomosis with protective stoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Patients operated for purulent or fecal peritonitis (Hinchey grade III and IV)&#xD;
             secondary to perforated diverticulitis of the left colon and treated by resection with&#xD;
             primary anastomosis&#xD;
&#xD;
          3. Person informed and having signed his consent. If the patient is unable to sign his&#xD;
             consent, the consent will be signed by his representative ((1) the trusted person, or&#xD;
             failing that, (2) a family member, or (3) a relative of the person concerned) (Article&#xD;
             L1122-1-1 of the CSP). In this case, consent to continue the study will subsequently&#xD;
             be requested from the patient. --&gt; In addition, due to the vital urgency represented&#xD;
             by hospitalisation in intensive care for purulent or fecal peritonitis, inclusion&#xD;
             without prior collection of the consent of the patient or his/her representative is&#xD;
             possible in the case where the patient is not capable of giving consent and his/her&#xD;
             representative is not present at the time of inclusion (Article L1122-1-3 of the CSP).&#xD;
             In this case, the patient or his/her representative will be informed as soon as&#xD;
             possible and his/her written consent will be requested for the possible continuation&#xD;
             of this research and the use of the data concerning him/her.&#xD;
&#xD;
          4. Patient able to comply with the study protocol, in the investigator's judgment&#xD;
&#xD;
          5. Patient affiliated with, or beneficiary of a social security (health insurance)&#xD;
             category&#xD;
&#xD;
        Non-inclusion Criteria:&#xD;
&#xD;
          1. Physical states that prevent patient participation (e.g. septic shock or multivisceral&#xD;
             failure)&#xD;
&#xD;
          2. Steroid treatment &gt; 20 mg daily&#xD;
&#xD;
          3. Prior pelvic irradiation&#xD;
&#xD;
          4. Immunocompromised status&#xD;
&#xD;
          5. Known progressive cancer&#xD;
&#xD;
          6. American Society of Anesthesiologists grade IV&#xD;
&#xD;
          7. Peritonitis secondary to perforated diverticulitis of the right colon&#xD;
&#xD;
          8. Patient is a pregnant (positive blood pregnancy test) or breastfeeding (lactating)&#xD;
             woman or intending to become pregnant during the study&#xD;
&#xD;
          9. Person deprived of liberty by administrative or judicial decision or placed under&#xD;
             judicial protection (guardianship or supervision)&#xD;
&#xD;
         10. Simultaneous participation in another interventional research&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Failure to obtain the consent of the patient or the patient's representative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie BRIDOUX</last_name>
    <phone>02 32 88 81 42</phone>
    <email>valerie.bridoux@chu-rouen.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Marc REGIMBEAU</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Marc REGIMBEAU</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CH Beauvais</name>
      <address>
        <city>Beauvais</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>François MAUVAIS</last_name>
    </contact>
    <investigator>
      <last_name>François MAUVAIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zaher LAKKIS</last_name>
    </contact>
    <investigator>
      <last_name>Zaher LAKKIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Avicenne</name>
      <address>
        <city>Bobigny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christophe TRESALLET</last_name>
    </contact>
    <investigator>
      <last_name>Christophe TRESALLET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Brest</name>
      <address>
        <city>Brest</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bogdan BADIC</last_name>
    </contact>
    <investigator>
      <last_name>Bogdan BADIC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Arnaud ALVES</last_name>
    </contact>
    <investigator>
      <last_name>Arnaud ALVES</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jean LUBRANO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne DUBOIS</last_name>
    </contact>
    <investigator>
      <last_name>Anne DUBOIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP Henri Mondor</name>
      <address>
        <city>Créteil</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas DE'ANGELIS</last_name>
    </contact>
    <investigator>
      <last_name>Nicolas DE'ANGELIS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Luc FAUCHERON</last_name>
    </contact>
    <investigator>
      <last_name>Jean-Luc FAUCHERON</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Muriel MATHONNET</last_name>
    </contact>
    <investigator>
      <last_name>Muriel MATHONNET</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eddy COTTE</last_name>
    </contact>
    <investigator>
      <last_name>Eddy COTTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura BEYER BERJOT</last_name>
    </contact>
    <investigator>
      <last_name>Laura BEYER BERJOT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHM La Timone</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane MEGE</last_name>
    </contact>
    <investigator>
      <last_name>Diane MEGE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nancy</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adeline GERMAIN</last_name>
    </contact>
    <investigator>
      <last_name>Adeline GERMAIN</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guillaume MEURETTE</last_name>
    </contact>
    <investigator>
      <last_name>Guillaume MEURETTE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Nimes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel PRUDHOMME</last_name>
    </contact>
    <investigator>
      <last_name>Michel PRUDHOMME</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>APHP St Antoine</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Yann PARC</last_name>
    </contact>
    <investigator>
      <last_name>Yann PARC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jeremie LEFEVRE</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie BRIDOUX</last_name>
    </contact>
    <investigator>
      <last_name>Valérie BRIDOUX</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehdi OUAISSI</last_name>
    </contact>
    <investigator>
      <last_name>Mehdi OUAISSI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 15, 2020</study_first_submitted>
  <study_first_submitted_qc>October 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 27, 2020</study_first_posted>
  <last_update_submitted>June 14, 2021</last_update_submitted>
  <last_update_submitted_qc>June 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peritonitis</keyword>
  <keyword>perforated diverticulitis</keyword>
  <keyword>primary anastomosis</keyword>
  <keyword>protective stoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peritonitis</mesh_term>
    <mesh_term>Diverticulitis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

